Adjunctive Antithrombotic Therapy for Primary PCI e375 Antiplatelet Therapy to Support Primary PCI for STEMI: Recommendations e375 Anticoagulant Therapy to Support Primary PCI: Recommendations e378 5. Reperfusion at a Non PCI-Capable Hospital e379 Fibrinolytic Therapy When There Is an Anticipated Delay to Performing Primary PCI Within 120 Minutes of FMC: Recommendations e379 Timing of Fibrinolytic Therapy e379 Choice of Fibrinolytic Agent e379 Contraindications and Complications With Fibrinolytic Therapy e380 5.1.4. Adjunctive Antithrombotic Therapy With Fibrinolysis e380 Adjunctive Antiplatelet Therapy With Fibrinolysis: Recommendations e380 Adjunctive Anticoagulant Therapy With Fibrinolysis: Recommendations e380 Assessment of Reperfusion After Fibrinolysis e381 Transfer to a PCI-Capable Hospital After Fibrinolytic Therapy e381 Transfer of Patients With STEMI to a PCI-Capable Hospital for Coronary Angiography After Fibrinolytic Therapy: Recommendations e381 Transfer for Cardiogenic Shock e382 Transfer for Failure of Fibrinolytic Therapy e382 Transfer for Routine Early Coronary Angiography After Fibrinolytic Therapy e382 6. Delayed Invasive Management e384 Coronary Angiography in Patients Who Initially Were Managed With Fibrinolytic Therapy or Who Did Not Receive Reperfusion: Recommendations e384 PCI of an Infarct Artery in Patients Initially Managed With Fibrinolysis or Who Did Not Receive Reperfusion Therapy: Recommendations e384 PCI of a Noninfarct Artery Before Hospital Discharge: Recommendations e385 Adjunctive Antithrombotic Therapy to Support Delayed PCI After Fibrinolytic Therapy e386 Antiplatelet Therapy to Support PCI After Fibrinolytic Therapy: Recommendations e386 Anticoagulant Therapy to Support PCI After Fibrinolytic Therapy: Recommendations e387 7. Coronary Artery Bypass Graft Surgery e387 CABG in Patients With STEMI: Recommendations e387 Timing of Urgent CABG in Patients With STEMI in Relation to Use of Antiplatelet Agents: Recommendations e388 8. Routine Medical Therapies e388 Beta Blockers: Recommendations e388 8.2. Renin-Angiotensin-Aldosterone System Inhibitors: Recommendations e390 Recommendations for Lipid Management e390 8.4. Nitrates e391 Calcium Channel Blockers e391 8.6. 